Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Radiology Devices Move To OIVD: More Cohesive Dx Reviews Ahead?

This article was originally published in The Gray Sheet

Executive Summary

FDA hopes that shuttling its Radiological Devices Branch to the Office of In Vitro Diagnostic Device Evaluation and Safety will produce more cohesive policies on diagnostic device review
Advertisement

Related Content

Dx Departure: US FDA's Diagnostics Chief Gutierrez Steps Down
OIVD Becomes OIR: FDA Diagnostic Office Adds Entire Radiological Health Program
OIVD Becomes OIR: FDA Diagnostic Office Adds Entire Radiological Health Program
CDRH Reorganization Proposal Would Add "Sorely Needed" Managers
OIVD In Brief
Tillman Departs: Device Evaluation Director To Leave FDA March 26
Radiology devices branch on the move
FDA Investigates CT Radiation Overdose In Multiple States, Facilities
FDA Whistleblower Letter Released At Sebelius Confirmation Hearing
Would Expanded Lab-Test Regulation Overstep FDA’s Legal Limits?

Topics

Advertisement
UsernamePublicRestriction

Register

MT028448

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel